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Abstract
Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is an increasing problem, predominantly in previously
healthy individuals including notable risk groups such as the homeless, those who play close-contact sports, military personnel, men
who have sex with men (MSM) and injecting drug users (IDUs). Over a 5-month period, four IDUs were admitted to Addenbrooke’s
Hospital, Cambridge, UK, with MRSA bacteraemia. All four patients presented with complex clinical features, with more than one focus
of infection, and were linked epidemiologically. The atypical antibiogram of the MRSA isolates (ciproﬂoxacin-susceptible) prompted
further characterization, both phenotypically (antibiotic resistance typing; phage typing) and genotypically (detection of toxin genes by
PCR; pulsed-ﬁeld gel electrophoresis (PFGE); Staphylococcal chromosome cassette (SCC) mec typing; multi-locus sequence typing
(MLST)). All four isolates had similar antibiograms, were Panton-Valentine Leucocidin (PVL) toxin gene-negative, harboured SCCmec
type IV and were closely related as shown by phage typing and PFGE. These isolates were representatives of a community-associated
clone, ST1-MRSA-IV, known to be circulating in IDUs in the UK since 2001. This paper presents a detailed description of the clinical,
microbiological and epidemiological features of a series of CA-MRSA bacteraemias in IDUs in the UK.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is a patho-
gen of key microbiological and public health signiﬁcance,
and is becoming increasingly important in the community.
Community-associated MRSA (CA-MRSA) ﬁrst appeared
about two decades ago and tended to affect previously
healthy individuals, with clusters occurring among speciﬁc
population groups such as military recruits and sports team
players. Over the past few years, other high-risk groups
have been identiﬁed, such as men who have sex with men
[1], people in jail [2], the district nurse patient population
[3], injecting drug users (IDUs) [4] and the homeless [5].
Alarmingly, CA-MRSA is now increasingly recognized out-
side these patient groups, and the current estimates of
prevalence in the UK general population are between
<0.1% and 1.5% [6,7].
Epidemiological characteristics of patients with CA-MRSA
infections are similar to those of patients with CA-methicillin-
susceptible S. aureus (MSSA) infections [8] but, at the
molecular level, CA-MRSA strains are different from health-
care-associated MRSA [9]. They tend to be more suscepti-
ble to non-b-lactam agents, carry smaller staphylococcal
chromosome cassette (SCC) mec types (usually type IV or
V) and often harbour the genes encoding the Panton-
Valentine leucocidin (PVL) virulence factor. Two clones
(USA300 and USA400) harbouring SCCmec type IVa and
PVL are found over a wide geographical area in the USA
[10]. These American clones are not yet common in the
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UK or elsewhere in Europe. In contrast, a speciﬁc clone
which does not encode the PVL toxin is circulating among
the IDU population in England and Wales. This was ﬁrst
apparent at the beginning of the millenium and continues to
be reported [11–13]. We describe the clinical, microbiologi-
cal and epidemiological features of four such isolates, col-
lected over a 5-month period (October 2006–February
2007), from cases of bacteraemia at Addenbrooke’s Hospi-
tal, Cambridge, UK.
Materials and Methods
The clinical case notes of the individual patients were
reviewed. Blood cultures were processed using the BacT-
Alert system (bioMe´rieux, Basingstoke, UK) in the Clinical
Microbiology and Public Health Laboratory, Health Protec-
tion Agency, Addenbrooke’s Hospital, Cambridge, UK. Initial
characterization of MRSA was performed according to
National Standard Methods (http://www.hpa-standardmeth-
ods.org.uk/documents/bsop/pdf/bsop29.pdf).
Phenotypic characterization of MRSA isolates
Methicillin susceptibility was determined using oxacillin strips
on salt agar. Other antibiotic susceptibility testing (R-type)
was performed in the diagnostic laboratory according to the
British Society of Antimicrobial Chemotherapy (BSAC)
method [14], and conﬁrmed by the Antibiotic Resistance
Evaluation Unit (HPA, Colindale, London) using agar dilution
for the determination of minimum inhibitory concentrations
(MIC) [14]. Phage typing was performed as described previ-
ously [15].
Genotypic characterization of MRSA isolates
Genotypic characterization included detection of toxin
genes by PCR, pulsed-ﬁeld gel electrophoresis (PFGE),
SCCmec typing and multi-locus sequence typing (MLST). All
MRSA isolates were screened for 14 staphylococcal toxin
genes: enterotoxins A–E and G–J, exfoliative toxins A, B
and D, toxic shock syndrome toxin-1 and PVL [15]. mecA
testing was performed as described previously [15]. PFGE
of SmaI-digested DNA was performed at the Staphylococ-
cus Reference Unit according to standard protocol [15].
The control strains were EMRSA-15 variant B1, and a
representative of the MRSA clone previously identiﬁed in
IDUs in the UK (isolated in a city other than Cambridge in
2006). Further typing was performed using multiplex PCR
according to the protocols of Zhang [16] for Class A/Class
B mec and Hanssen [28] for ccr gene complex. MLST was
performed as described by Enright [17], and sequence type
(ST) assignment was based on the sequence of the alleles
at each locus of seven housekeeping genes, using the MLST
database (http://www.mlst.net).
Results
Over a 5-month period, four cases of bacteraemia as a result
of MRSA with an unusual antibiogram (susceptible to cipro-
ﬂoxacin and resistant to erythromycin and fusidic acid) were
seen in IDUs admitted to our hospital. The clinical cases are
given below.
Case A
Case A as a 24-year-old HIV-negative Caucasian male who
presented in February 2007 with a short history of rigors,
sweating, painful legs and haemoptysis. He was a known her-
oin injector and had a history of deep vein thrombosis
(DVT) associated with cellulitis in 2005. Blood cultures at
the time of the cellulitis were negative and no aetiological
factor was identiﬁed at the time. On clinical examination in
February 2007 he had needle tracks in his right groin, which
looked infected clinically. Blood cultures were drawn at
admission. Chest radiography revealed that he had multiple
pulmonary abscesses in the right lung ﬁeld. No evidence
of airway bleeding or parenchymal bleeding was present. His
C-reactive protein (CRP) was 155 mg/L. He was not investi-
gated for pulmonary embolism as he had very poor venous
access and a trans-thoracic echocardiogram (TTE) was nor-
mal. Investigations for recurrent DVT were negative. The
patient absconded on the day of admission, but returned
later that day and was started on intravenous ﬂucloxacillin.
On day 3, intravenous vancomycin was commenced, as the
admission blood culture grew MRSA. He self-discharged on
day 4 of hospitalization and was lost to follow-up.
Case B
Case B was a 40-year-old HIV-negative male who was admit-
ted in November 2006. He was a current IDU and had a
history of fever, sweating and rapid breathing. On clinical
examination he was septic with a right pleural effusion. On day
5 of hospitalization, ultrasound of the chest revealed consoli-
dation of the right lower lobe. He had possible multiple pulmo-
nary abscesses on CT imaging of the chest. TTE and magnetic
resonance imaging (MRI) of the spine were normal. One of
two blood culture bottles taken on admission yielded MRSA,
with Group A streptococcus also being cultured from both
bottles. On day 17 of hospitalization he was diagnosed with a
right-sided DVT in the central and superﬁcial femoral veins. In
addition, blood cultures taken on day 18 grew Candida spp. He
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was treated initially with ciproﬂoxacin monotherapy, and sub-
sequently with intravenous vancomycin paired with a single
oral agent (clindamycin, followed by rifampicin, followed by
ciproﬂoxacin, in succession, because of side effects), as well as
antifungal agents. Vancomycin was stopped as a result of neu-
tropenia and he was changed to oral treatment with rifampicin
and ciproﬂoxacin; he received a total of 28 days anti-staphylo-
coccal treatment. He remained in hospital for a total of
35 days and was discharged on oral rifampicin and ciproﬂoxa-
cin for a further 14 days, giving a total of 49 days of antibiotic
therapy. His compliance with the antibiotic prescription during
his outpatient treatment is not known. He was readmitted in
January 2007, 5 days after he would have theoretically discon-
tinued his oral antibiotics, with bilateral lower leg abscesses.
Blood cultures could not be taken because of access problems.
The patient received 1 day of intravenous vancomycin and
5 days of intramuscular teicoplanin, followed by 6 weeks of
oral rifampicin and ciproﬂoxacin. He has not attended hospital
appointments since and is lost to follow-up.
Case C
Case C was a 40-year-old male who was admitted in October
2006 with his second episode of MRSA bacteraemia. He was
a known IDU, who was HIV-negative, and had a 5-day history
of cough with sputum production and left-sided chest pain.
He had a past medical history of empyema in 2004 and bilat-
eral ante-cubital abscesses in 2005. In May 2006 he developed
cellulitis and abscesses of the left thigh which contained
MSSA, necessitating drainage, and bacteraemia with MRSA.
These isolates were not submitted for further typing. On
examination in October 2006 he had a right femoral aneu-
rysm and chest radiography revealed a right empyema and
pneumonia with multiple areas of consolidation. There was
no evidence of airway or parenchymal bleeding. His CRP was
238 g/L and blood gas analysis showed a metabolic acidosis.
He required continuous positive airway pressure (CPAP) sup-
port in the Intensive Therapy Unit (ITU). Blood cultures
taken on admission (18.10.06) yielded MRSA. He received
2 weeks of intravenous vancomycin and was subsequently
prescribed 2 weeks of doxycycline and rifampicin therapy.
Unfortunately he defaulted on treatment. This patient was re-
admitted in March 2007 with osteomyelitis after malunion of
a scaphoid fracture, associated with bacteraemia as a result of
MSSA (susceptible to erythromycin and fusidic acid) and read-
mitted again with recurrent infection in May 2007, at which
point he had a Streptococcus mitis bacteraemia.
Case D
Case D was a 40-year-old HIV-negative male who was a
known IDU. He ﬁrst presented in October 2006 with
a history of back pain and shortness of breath. He had a
past medical history of cellulitis in 2001 and was positive
for hepatitis C virus. He was diagnosed with discitis with
osteomyelitis at T8/T9 on MRI with gadolinium enhance-
ment. Blood cultures from all six bottles taken on admission
yielded MRSA, and he received 8 weeks of intravenous
vancomycin. This was followed by oral rifampicin and doxy-
cycline. In September 2007, a repeat MRI of the patient’s
lumbar spine, because of recurrence of lower back pain, did
not show any evidence of residual infection.
Patient D, male. First
positive blood culture
16/02/07, admits to
needle sharing.
Patient C, male. First
positive blood culture
21/05/06;
Second blood
culture positive  
18/10/06.
Patient A, male. First
positive blood culture
16/02/07
Patient B. Male. First
Positive blood culture
02/11/06
Patient X, female.
No positive blood
culture. Positive groin swab
isolate 30/11/06, large
bilateral groin
abscesses drained
13/01/07
Other connections between patients: Patient X
shared residence with patients B and A during
2006 and 2007, respectively. 
Patients B and C were friends and spent time
together during 2006 and 2007.
Patients A and C were also friends and spent
time together during 2006 and 2007. 
FIG. 1. Known epidemiological links be-
tween cases A–D.
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Epidemiology
The four individuals lived at different addresses in Cambridge-
shire and came into contact with each other over the course
of their presentations. Their known associations are pre-
sented in Fig. 1. Patients A and C were connected through
both being ‘friends’ with patient B. Patient D had admitted
sharing needles on various occasions with other local
Cambridge IDUs although no direct connection between him
and the other patients was elucidated. A ﬁfth patient (patient
X) presented with a clinical picture similar to those of the
four cases described. Ciproﬂoxacin-susceptible MRSA was
cultured from a wound swab in October 2006, 2 months
before she presented with severe bilateral thigh abscesses.
Blood cultures or pus samples were not obtainable. This
patient resided at the same address as two of the patients in
this series, albeit over separate times. All of these patients,
with the exception of patient D, had slept at least overnight
in at least one of the few Cambridge hostels.
Phenotypic and molecular investigations
Detailed phenotypic and genotypic characterization of isolates
was performed because all four isolates were ciproﬂoxacin
susceptible (an unusual ﬁnding for classic HA-MRSA in the
UK) (Table 1). In summary, all four were resistant to b-lactams,
erythromycin and fusidic acid, and one isolate exhibited
additional resistance to gentamicin. All four harboured the
mecA gene and gave indistinguishable phage patterns (lysed
by Group I/III phages). Three isolates were subjected to
MLST and were ST1. All four MRSA isolates harboured
SCCmec type IV (class B mec complex and ccrAB2 ccr com-
plex) (Table 1). The toxin gene proﬁles were similar: all
were PVL negative but harboured seh (enterotoxin gene H);
three of four isolates also encoded sea (enterotoxin gene A).
They were closely related by PFGE according to the criteria
of Tenover et al. [21] and three isolates were indistinguish-
able from a control strain of ST1-MRSA-IV from an IDU
elsewhere in the UK (Fig. 2). The fourth isolate (Lane 3,
patient A) shows a band shift but was closely related to the
remainder; this was the gentamicin-resistant isolate.
Discussion
The identiﬁcation of four ciproﬂoxacin-susceptible MRSA iso-
lates over a 5-month period from blood cultures of patients
known to inject drugs prompted review of the clinical cases
together with molecular epidemiologic investigations. The
cases of bacteraemia we describe were all associated with
involvement of multiple clinical sites, including soft tissues as
well as lung tissue (Table 1). None of the pneumonias was
clinically necrotizing, as commonly described with CA-MRSA
which are PVL-positive, in that there was no clinical or radio-
graphic evidence of haemorrhage. All patients survived the
event. As the cases involved IDUs, difﬁculties in management
included (i) establishing intravenous access; (ii) performing
blood cultures appropriately without using potentially colo-
nized or infected sites; (iii) completing treatment; and (iv)
issues with compliance and follow-up.
A study from South London between 2000 and 2006 iden-
tiﬁed probable CA-MRSA infection (using ciproﬂoxacin sus-
ceptibility as a marker) in 65 patients with medical record
evidence of injecting drug use or alcohol abuse [18]. Of the
corresponding isolates, only seven were from blood cultures,
averaging one bacteraemia per year. Clearly our cluster of
four bacteraemic cases in ﬁve months was highly unusual.
There have been no cases of bacteraemia with ciproﬂoxacin-
TABLE 1. Cases of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: details of clinical infections, antibiotic
treatment, phenotypic and genotypic characteristics of isolates
Case
Gender,
age
(years)
Date of
blood
culture R-type
Phage
type
PVL
toxin
genes
Other
toxin
genes MLST
SCCmec
type Likely clinical focus Antibiotic treatment
A M, 24 16.02.07 Oxa, Ery,
Fus, Gent
Aa Neg Sea; seh ST1 IV Pulmonary abscesses
Cellulitis
Flucloxacillin · 2/7 Vancomycin ·
1/12; self-discharged
B M, 40 2.11.06 mixed with
Group A
Streptococcus
Oxa, Ery, Fus A Neg seh Not done IV Pulmonary abscesses
Pneumonia pleural effusion
Deep venous
thrombosis (DVT)
Resolving groin abscess
Ciproﬂoxacin · 8/7, followed by
(Vancomycin, see text + Rifampicin) ·
1/12 Clindamycin · 2/52 (in
view of Group A Streptococcus)
C M, 40 21.05.06 Oxa, Ery, Fus Not done Neg sea; seh Not done Not done Bacteraemia Vancomycin
18.10.06 Oxa, Ery, Fus A Neg sea; seh ST1 IV Empyema pneumonia
Previous cellulitis
Vancomycin · 2/52; self-discharged
after this
D M, 40 13.10.06 Oxa, Ery, Fus A Neg sea; seh ST1 IV Osteomyelitis
Discitis T8/T9
Vancomycin · 2/12, followed by oral
Rifampicin and Doxycycline
aIsolates gave indistinguishable patterns and were lysed by group I/III phages.
Oxa, oxacillin; Ery, erythromycin; Fus, fusidic acid; Gent, gentamicin.
sea = enterotoxin gene A; seh = enterotoxin gene H.
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susceptible MRSA in IDUs admitted to our hospital between
February 2007 and December 2008.
Resistance typing revealed that three isolates were resis-
tant to b-lactams, erythromycin and fusidic acid, and the
fourth isolate (from patient A) also exhibited resistance to
gentamicin. There was no record of patient A having
received gentamicin at our hospital. The association of fusidic
acid resistance in MRSA isolates from IDUs in the UK was
ﬁrst highlighted by Corkill et al. [19], from the Royal
Liverpool University Hospital. They reported an increasing
number of fusidic acid-resistant MRSA isolates between 2001
and 2003 (5% in 2001, 7% in 2002 and 12% in the ﬁrst
8 months of 2003), whereas the rate of fusidic acid resis-
tance in MSSA remained at a constant 13%. Although this
Liverpool study involved the general population, the ﬁndings
concerning the IDU patients had ﬁrst alerted the authors to
this association. The isolates of MRSA causing bacteraemias
in IDUs were clonal as shown by PFGE [20].
The ST1-MRSA-IV clone has been reported previously in
Australia where it is known as WA-MRSA-1 [22]. It has
also been identiﬁed in neonatal units in the UK [23–25]
and is known to have been circulating among IDUs in Eng-
land and Wales since approximately 2001 [26]. Between
April 2003 and March 2007, 60 isolates of MRSA from
IDUs were received by the HPA Staphylococcus Reference
Unit for analysis from different areas of England and Wales.
Twenty-one of these 60 isolates (35%) were from cases of
bacteraemia, 30 were from patients with injection site
abscesses or skin infections, four were from patients with
endocarditis, and one was from a patient with pneumonia
(clinical data are not available for the remaining four) [27].
The ST1-MRSA-IV clone is distinct from healthcare-associ-
ated MRSA in the UK (EMRSA-15 and EMRSA-16). Although
this community-associated clone does not produce the PVL
toxin, it can cause skin and soft tissue infection (SSTI) [28].
In our homeless community in Cambridge, UK, MRSA is a
known cause of SSTIs. A retrospective study of SSTIs as a
result of MRSA in people who were homeless or at risk of
homelessness in 2006–2007 found that 80% (68/85) of MRSA
infections occurred in known IDUs [5].
In summary, isolates belonging to the ST1-MRSA-IV line-
age were responsible for four cases of bacteraemia in
IDUs in Cambridge. These cases were complicated in
terms of presentation, involvement of several clinical sites,
and the complex management issues surrounding this pop-
ulation group. There were known epidemiological links
among three individuals, and molecular typing showed that
all four carried isolates of the the ST1-MRSA-IV lineage
which is known to be circulating among IDUs in England
and Wales. To improve our understanding of the epidemi-
ology and burden of disease associated with this lineage,
other centres need to remain vigilant to ensure that cases
do not go unrecognized.
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FIG. 2. Macrorestriction of chromosomal DNA, digested with SmaI
and visualized by pulsed-ﬁeld gel electrophoresis (PFGE). The
sequence types (ST) are also marked (ND, Not Done); Lane
1 = EMRSA-15, variant B1 control strain; Lane 2 = Patient B;
Lane 3 = Patient A; Lane 4 = Patient C; Lane 5 = Patient D; Lane
6 = HPA control isolate from known IDU.
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